Version 1
: Received: 20 May 2024 / Approved: 20 May 2024 / Online: 20 May 2024 (20:18:17 CEST)
How to cite:
Włodarczak, S.; Rola, P.; Jastrzębski, A.; Turkiewicz, K.; Korda, A.; Włodarczak, P.; Barycki, M.; Kulczycki, J. J.; Furtan, Ł.; Włodarczak, A.; Lesiak, M. Safety and Effectiveness of Coronary Sinus Reducer in the Therapy of Refractory Angina Pectoris - Mid-Term Results of the Real-Life Cohort. Preprints2024, 2024051305. https://doi.org/10.20944/preprints202405.1305.v1
Włodarczak, S.; Rola, P.; Jastrzębski, A.; Turkiewicz, K.; Korda, A.; Włodarczak, P.; Barycki, M.; Kulczycki, J. J.; Furtan, Ł.; Włodarczak, A.; Lesiak, M. Safety and Effectiveness of Coronary Sinus Reducer in the Therapy of Refractory Angina Pectoris - Mid-Term Results of the Real-Life Cohort. Preprints 2024, 2024051305. https://doi.org/10.20944/preprints202405.1305.v1
Włodarczak, S.; Rola, P.; Jastrzębski, A.; Turkiewicz, K.; Korda, A.; Włodarczak, P.; Barycki, M.; Kulczycki, J. J.; Furtan, Ł.; Włodarczak, A.; Lesiak, M. Safety and Effectiveness of Coronary Sinus Reducer in the Therapy of Refractory Angina Pectoris - Mid-Term Results of the Real-Life Cohort. Preprints2024, 2024051305. https://doi.org/10.20944/preprints202405.1305.v1
APA Style
Włodarczak, S., Rola, P., Jastrzębski, A., Turkiewicz, K., Korda, A., Włodarczak, P., Barycki, M., Kulczycki, J. J., Furtan, Ł., Włodarczak, A., & Lesiak, M. (2024). Safety and Effectiveness of Coronary Sinus Reducer in the Therapy of Refractory Angina Pectoris - Mid-Term Results of the Real-Life Cohort. Preprints. https://doi.org/10.20944/preprints202405.1305.v1
Chicago/Turabian Style
Włodarczak, S., Adrian Włodarczak and Maciej Lesiak. 2024 "Safety and Effectiveness of Coronary Sinus Reducer in the Therapy of Refractory Angina Pectoris - Mid-Term Results of the Real-Life Cohort" Preprints. https://doi.org/10.20944/preprints202405.1305.v1
Abstract
Background: Despite continuous improvements in revascularization techniques, refractory angina without potential revascularization options remains a relevant clinical issue with significant impact on patient’s quality of life. Recently, a novel device, the Coronary Sinus Reducer (CSR), has been introduced into clinical practice as a therapeutic option for patients with disabling angina pectoris. In this single-center, observational study, we evaluated the mid-term (3-month) safety and efficacy of the CSR in a real-world cohort. Methods: The study population consisted of 55 patients with refractory angina without potential revascularization options, predominantly men (87.3%) with a high cardiovascular risk factor burden and advanced angina (baseline CCS angina class 3.15 ± 0.6). In terms of procedure safety, all patients underwent successful device deployment with only one periprocedural complication. Results: At the 3-month follow-up we observed statistically significant improvement in angina control measured CCS class and SAQ-7 Total questionnaire along with increased abolition of physical limitation – 6-MWT (233.3 ± 107.1 vs 305.2 ± 126.8; p<0.0001). Additionally, we observed significant improvement in terms of quality of life measurements SF-36, the EQ-5D-5L questionnaire, and the EQ-VAS. Conclusions: Our real-world data suggest that CSR implantation is a relatively safe procedure and appears to be particularly effective in relieving angina symptoms and improving quality of life in subjects with refractory angina.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
